Zoetis Announces Pricing of $1.25 Billion of Senior Notes
Zoetis Inc. (NYSE:ZTS) today announced that it has agreed to sell $1.25 billion of senior notes, consisting of $750 million
aggregate principal amount of 3.000% senior notes due 2027 and $500 million aggregate principal amount of 3.950% senior notes due
2047, in an underwritten public offering.
Zoetis intends to use the net proceeds to repay, prior to maturity, the principal (including a make-whole amount) of its 1.875%
senior notes due 2018 in the aggregate principal amount of $750 million; and for general corporate purposes. The offering is
expected to close on September 12, 2017, subject to customary closing conditions.
Barclays Capital Inc., Citigroup Global Markets Inc., J.P. Morgan Securities LLC, Merrill Lynch, Pierce, Fenner & Smith
Incorporated and MUFG Securities Americas Inc. are acting as joint book-running managers of the underwriters. The final prospectus
supplement and accompanying prospectus, when available, may be accessed through the SEC’s website at www.sec.gov. Alternatively, the issuer, the underwriters or any dealer participating in the offering will
arrange to send you the prospectus and prospectus supplement if you request it by calling Barclays at 1-888-603-5847, BofA Merrill
Lynch at 1-800-294-1322, Citigroup at 1-800-831-9146, J.P. Morgan at 212-834-4533 and MUFG at 1-877-649-6848.
These securities are offered pursuant to a registration statement that has become effective under the Securities Act of 1933, as
amended. These securities are only offered by means of the prospectus supplement and prospectus relating to the offering. This
press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any offer or sale of
these securities in any state or other jurisdiction, where the offer, solicitation or sale of these securities would be unlawful
prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About Zoetis
Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than
60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines,
complemented by diagnostic products, genetic tests, biodevices and a range of services. Zoetis serves veterinarians, livestock
producers and people who raise and care for farm and companion animals with sales of its products in more than 100 countries.
DISCLOSURE NOTICES
Forward-Looking Statements : This press release contains forward-looking statements,
which reflect the current views of Zoetis with respect to business plans or prospects, future operating or financial performance,
future guidance, future operating models, expectations regarding products, future use of cash and dividend payments, tax rate and
tax regimes, changes in the tax regimes and laws in other jurisdictions, and other future events. These statements
are not guarantees of future performance or actions. Forward-looking statements are subject to risks and uncertainties. If one or
more of these risks or uncertainties materialize, or if management's underlying assumptions prove to be incorrect, actual results
may differ materially from those contemplated by a forward-looking statement. Forward-looking statements speak only as of the date
on which they are made. Zoetis expressly disclaims any obligation to update or revise any forward-looking statement, whether as a
result of new information, future events or otherwise. A further list and description of risks, uncertainties and other
matters can be found in the prospectus supplement and accompanying prospectus under the caption “Risk Factors” and in our Annual
Report on Form 10-K for the fiscal year ended December 31, 2016, including in the sections thereof captioned “Forward-Looking
Statements and Factors That May Affect Future Results” and “Item 1A. Risk Factors,” in our Quarterly Reports on Form 10-Q and in
our Current Reports on Form 8-K. These filings and subsequent filings are available online at www.sec.gov , Zoetis’ website, or on request from Zoetis.
Zoetis Inc.
Media:
Bill Price, 1-973-443-2742 (o)
william.price@zoetis.com
or
Elinore White, 1-973-443-2835 (o)
elinore.y.white@zoetis.com
or
Investors:
Steve Frank, 1-973-822-7141 (o)
steve.frank@zoetis.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20170905006538/en/